489 related articles for article (PubMed ID: 26249178)
1. A Molecular Portrait of High-Grade Ductal Carcinoma In Situ.
Abba MC; Gong T; Lu Y; Lee J; Zhong Y; Lacunza E; Butti M; Takata Y; Gaddis S; Shen J; Estecio MR; Sahin AA; Aldaz CM
Cancer Res; 2015 Sep; 75(18):3980-90. PubMed ID: 26249178
[TBL] [Abstract][Full Text] [Related]
2. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
3. Multi-omic profiling of simultaneous ductal carcinoma in situ and invasive breast cancer.
Kaplan HG; Dowdell AK; Berry AB; Shimol RB; Robinson FL; Carney CA; Piening BD
Breast Cancer Res Treat; 2024 Jun; 205(3):451-464. PubMed ID: 38523186
[TBL] [Abstract][Full Text] [Related]
4. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast.
Kominsky SL; Argani P; Korz D; Evron E; Raman V; Garrett E; Rein A; Sauter G; Kallioniemi OP; Sukumar S
Oncogene; 2003 Apr; 22(13):2021-33. PubMed ID: 12673207
[TBL] [Abstract][Full Text] [Related]
5. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
[TBL] [Abstract][Full Text] [Related]
6. Multi-omics portrait of ductal carcinoma in situ in young women.
Hong R; Cao B; Chen D; Wu W; Luo T; Lv D; Zhang W; Wang S; Shao K
Breast Cancer Res Treat; 2024 Jul; 206(1):105-118. PubMed ID: 38704773
[TBL] [Abstract][Full Text] [Related]
7. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast.
Vincent-Salomon A; Lucchesi C; Gruel N; Raynal V; Pierron G; Goudefroye R; Reyal F; Radvanyi F; Salmon R; Thiery JP; Sastre-Garau X; Sigal-Zafrani B; Fourquet A; Delattre O;
Clin Cancer Res; 2008 Apr; 14(7):1956-65. PubMed ID: 18381933
[TBL] [Abstract][Full Text] [Related]
8. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling.
Kristensen VN; Vaske CJ; Ursini-Siegel J; Van Loo P; Nordgard SH; Sachidanandam R; Sørlie T; Wärnberg F; Haakensen VD; Helland Å; Naume B; Perou CM; Haussler D; Troyanskaya OG; Børresen-Dale AL
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2802-7. PubMed ID: 21908711
[TBL] [Abstract][Full Text] [Related]
9. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.
Toss MS; Abidi A; Lesche D; Joseph C; Mahale S; Saunders H; Kader T; Miligy IM; Green AR; Gorringe KL; Rakha EA
Br J Cancer; 2020 May; 122(10):1496-1506. PubMed ID: 32203210
[TBL] [Abstract][Full Text] [Related]
10. Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer.
Kim SY; Jung SH; Kim MS; Baek IP; Lee SH; Kim TM; Chung YJ; Lee SH
Oncotarget; 2015 Apr; 6(10):7597-607. PubMed ID: 25831047
[TBL] [Abstract][Full Text] [Related]
11. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells.
Krop IE; Sgroi D; Porter DA; Lunetta KL; LeVangie R; Seth P; Kaelin CM; Rhei E; Bosenberg M; Schnitt S; Marks JR; Pagon Z; Belina D; Razumovic J; Polyak K
Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9796-801. PubMed ID: 11481438
[TBL] [Abstract][Full Text] [Related]
12. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
[TBL] [Abstract][Full Text] [Related]
13. Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions.
Mardekian SK; Bombonati A; Palazzo JP
Hum Pathol; 2016 Mar; 49():114-23. PubMed ID: 26826418
[TBL] [Abstract][Full Text] [Related]
14. Patterns of chromosomal alterations in breast ductal carcinoma in situ.
Hwang ES; DeVries S; Chew KL; Moore DH; Kerlikowske K; Thor A; Ljung BM; Waldman FM
Clin Cancer Res; 2004 Aug; 10(15):5160-7. PubMed ID: 15297420
[TBL] [Abstract][Full Text] [Related]
15. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
16. Concordant loss of fragile gene expression early in breast cancer development.
Guler G; Uner A; Guler N; Han SY; Iliopoulos D; McCue P; Huebner K
Pathol Int; 2005 Aug; 55(8):471-8. PubMed ID: 15998374
[TBL] [Abstract][Full Text] [Related]
17. FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast.
Lal A; Chan L; Devries S; Chin K; Scott GK; Benz CC; Chen YY; Waldman FM; Hwang ES
Breast Cancer Res Treat; 2013 Jun; 139(2):381-90. PubMed ID: 23712790
[TBL] [Abstract][Full Text] [Related]
18. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
van der Groep P; van Diest PJ; Menko FH; Bart J; de Vries EG; van der Wall E
J Clin Pathol; 2009 Oct; 62(10):926-30. PubMed ID: 19541683
[TBL] [Abstract][Full Text] [Related]
19. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.
Sharma M; Beck AH; Webster JA; Espinosa I; Montgomery K; Varma S; van de Rijn M; Jensen KC; West RB
Breast Cancer Res Treat; 2010 Sep; 123(2):397-404. PubMed ID: 19949854
[TBL] [Abstract][Full Text] [Related]
20. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia.
Knudsen ES; Ertel A; Davicioni E; Kline J; Schwartz GF; Witkiewicz AK
Breast Cancer Res Treat; 2012 Jun; 133(3):1009-24. PubMed ID: 22134623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
